BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/2/2022 10:47:24 AM | Browse: 130 | Download: 298
Publication Name World Journal of Gastroenterology
Manuscript ID 79932
Country/Territory India
Received
2022-09-12 11:06
Peer-Review Started
2022-09-12 11:07
To Make the First Decision
Return for Revision
2022-09-29 21:02
Revised
2022-10-07 10:10
Second Decision
2022-11-16 03:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-11-17 23:00
Articles in Press
2022-11-17 23:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
2022-11-10 18:42
Typeset the Manuscript
2022-11-23 10:03
Publish the Manuscript Online
2022-12-02 09:49
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Evidence Review
Article Title COVID-19 drug-induced liver injury: A recent update of the literature
Manuscript Source Invited Manuscript
All Author List Lekha Saha, Soumya Vij and Kajal Rawat
Funding Agency and Grant Number
Corresponding Author Lekha Saha, MBBS, MD, MNAMS, Full Professor, Professor, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. lekhasaha@rediffmail.com
Key Words Liver injury; COVID-19; Anti-COVID drugs; Mechanisms; Clinical evidences
Core Tip Liver damage is cited as the most frequent clinical extrapulmonary manifestation in a number of coronavirus disease 2019 (COVID-19) clinical trials. Herein, we summarized the available clinical data concerning liver injury during COVID-19. Transaminases and bilirubin levels were high in a significant majority of patients; however, the exact cause of liver damage is not entirely clear. A worse clinical course of COVID-19 may be associated with severe liver enzyme abnormalities. However, it is impossible to rule out a number of additional cofactors (drug-induced liver damage, an inflammatory response to an infection, hypoxic hepatitis, or underlying liver disease).
Publish Date 2022-12-02 09:49
Citation Saha L, Vij S, Rawat K. COVID-19 drug-induced liver injury: A recent update of the literature. World J Gastroenterol 2022; 28(45): 6314-6327
URL https://www.wjgnet.com/1007-9327/full/v28/i45/6314.htm
DOI https://dx.doi.org/10.3748/wjg.v28.i45.6314
Full Article (PDF) WJG-28-6314.pdf
Full Article (Word) WJG-28-6314.docx
Manuscript File 79932_Auto_Edited-LM.docx
Answering Reviewers 79932-Answering reviewers.pdf
Audio Core Tip 79932-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 79932-Conflict-of-interest statement.pdf
Copyright License Agreement 79932-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 79932-Language certificate.pdf
Peer-review Report 79932-Peer-review(s).pdf
Scientific Misconduct Check 79932-Bing-Wang JJ-2.png
Scientific Editor Work List 79932-Scientific editor work list.pdf